My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 180

    1.

    Tolerability of rofecoxib versus naproxen.

    Rusche JM.

    Ann Intern Med. 2004 Jun 15;140(12):1059; author reply 1060. No abstract available. PMID: 15197028 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Tolerability of rofecoxib versus naproxen.

    Jenkinson ML.

    Ann Intern Med. 2004 Jun 15;140(12):1059-60; author reply 1060. No abstract available. PMID: 15197027 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Tolerability of rofecoxib versus naproxen.

    Hanauer LB.

    Ann Intern Med. 2004 Jun 15;140(12):1059; author reply 1060. No abstract available. PMID: 15197026 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Summaries for patients. Gastrointestinal side effects of rofecoxib and naproxen.

    [No authors listed]

    Ann Intern Med. 2003 Oct 7;139(7):I29. No abstract available. PMID: 14530248 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial.

    Lisse JR, Perlman M, Johansson G, Shoemaker JR, Schechtman J, Skalky CS, Dixon ME, Polis AB, Mollen AJ, Geba GP; ADVANTAGE Study Group.

    Ann Intern Med. 2003 Oct 7;139(7):539-46.PMID: 14530224 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Is rofecoxib safer than naproxen?

    Adelman A.

    J Fam Pract. 2001 Mar;50(3):204. No abstract available. PMID: 11252204 [PubMed - indexed for MEDLINE]Related articles

    7.

    Report of specific cardiovascular outcomes of the ADVANTAGE trial.

    Braunstein N, Polis A.

    Ann Intern Med. 2005 Jul 19;143(2):158-9. Epub 2005 Jun 20. No abstract available. PMID: 15968005 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Lower gastrointestinal complications of nonsteroidal anti-inflammatory drugs.

    Schiller LR.

    Curr Gastroenterol Rep. 2003 Oct;5(5):397-8. No abstract available. PMID: 12959720 [PubMed - indexed for MEDLINE]Related articles

    9.

    Upper gastrointestinal toxicity of rofecoxib and naproxen.

    Gupta S.

    N Engl J Med. 2001 May 3;344(18):1398; author reply 1398-9. No abstract available. PMID: 11336057 [PubMed - indexed for MEDLINE]Related articles

    10.

    The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.

    Sowers JR, White WB, Pitt B, Whelton A, Simon LS, Winer N, Kivitz A, van Ingen H, Brabant T, Fort JG; Celecoxib Rofecoxib Efficacy and Safety in Comorbidities Evaluation Trial (CRESCENT) Investigators.

    Arch Intern Med. 2005 Jan 24;165(2):161-8. Erratum in: Arch Intern Med. 2005 Mar 14;165(5):551. PMID: 15668361 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    The lessons of Vioxx.

    Frazier KC.

    N Engl J Med. 2005 Sep 29;353(13):1420-1; author reply 1420-1. No abstract available. PMID: 16192497 [PubMed - indexed for MEDLINE]Related articles

    12.

    Rofecoxib and the risk of adverse upper gastrointestinal effects.

    Whitney E.

    JAMA. 2000 Apr 19;283(15):1960; author reply 1961. No abstract available. PMID: 10789660 [PubMed - indexed for MEDLINE]Related articles

    13.

    Risk of cardiovascular events and rofecoxib: cumulative meta-analysis.

    Jüni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M.

    Lancet. 2004 Dec 4-10;364(9450):2021-9.PMID: 15582059 [PubMed - indexed for MEDLINE]Related articles

    14.

    Rofecoxib and the risk of adverse upper gastrointestinal effects.

    Freston J.

    JAMA. 2000 Apr 19;283(15):1960; author reply 1961. No abstract available. PMID: 10789659 [PubMed - indexed for MEDLINE]Related articles

    15.

    Increased risk of cardiovascular events with coxibs and NSAIDs.

    Emery P, Moore A, Hawkey C.

    Lancet. 2005 Apr 30-May 6;365(9470):1538. No abstract available. PMID: 15866301 [PubMed - indexed for MEDLINE]Related articles

    16.

    Discontinuation of Vioxx.

    Nyberg J.

    Lancet. 2005 Jan 1-7;365(9453):24-5; author reply 26-7. No abstract available. PMID: 15639670 [PubMed - indexed for MEDLINE]Related articles

    17.

    Coxibs and cardiovascular disease.

    Fitzgerald GA.

    N Engl J Med. 2004 Oct 21;351(17):1709-11. Epub 2004 Oct 6. No abstract available. PMID: 15470192 [PubMed - indexed for MEDLINE]Related articles

    18.

    Are selective COX 2 inhibitors superior to traditional NSAIDs? Rofecoxib did not provide unequivocal benefit over traditional NSAIDs.

    Budenholzer BR.

    BMJ. 2002 Jul 20;325(7356):161; author reply 161. No abstract available. PMID: 12130617 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Blood pressure control and rates of edema following the administration of the cyclooxygenase-2 specific inhibitors celecoxib versus rofecoxib in patients with systemic hypertension and osteoarthritis.

    Weaver A, Alderman M, Sperling R.

    Am J Cardiol. 2003 May 15;91(10):1291-2. No abstract available. PMID: 12745131 [PubMed - indexed for MEDLINE]Related articles

    20.

    Discontinuation of Vioxx.

    Kim PS, Reicin AS.

    Lancet. 2005 Jan 1-7;365(9453):23; author reply 26-7. No abstract available. PMID: 15639669 [PubMed - indexed for MEDLINE]Related articles

    Display Settings:

    Format
    Items per page
    Sort by

    Send to:

    Choose Destination

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity